Spectroscopy in Parkinson Disease

Molecular Biometrics, Inc.500 enrolled

Overview

The primary objective of the study is to determine the utility of blood plasma infrared spectroscopy (biospectroscopy) in distinguishing subjects with idiopathic Parkinson's disease from healthy controls.

Oxidative stress has been implicated as a factor in the pathogenesis of Parkinson's disease (PD). The overall goal of this proposal is to use a novel metabolomics platform, based on near infrared biospectroscopy, to detect oxidatively modified blood plasma constituents. These spectral findings can be used to model the degree of oxidative stress with a modeled "stress index" that may distinguish PD cases from healthy elderly controls.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Parkinson Disease

Interventions

Blood drawOTHER

Blood draw, two tubes, used for isolation of cell-free blood plasma

Eligibility

Sex: ALLMin age: 46 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: PD Subjects: 1. PostCEPT subjects with a diagnosis of PD based on UK Brain Bank criteria. 2. Willing and able to provide informed consent. Healthy Controls: 1. No current diagnosis or known history of a neurological disease/disorder. 2. Non-blood relative of a patient or subject at the site who has diagnosis of PD (may include healthy controls from the PROBE study). 3. No first degree relatives with diagnosis of PD 4. MoCA score \> 26. 5. Age \> 45. 6. Willing and able to provide informed consent.

Locations (1)

University of Rochester

Rochester, New York, United States

Outcomes

Primary Outcomes

The primary outcome of the study is the correct classification of cases of PD and controls. This will be quantified as sensitivity and specificity.

Time frame: Baseline and annually for two years

Secondary Outcomes

Determine impact of disease stage, age, gender, medications, cognitive scores, other laboratory measures (e.g. alpha-synuclein) and other clinical/demographic variables on plasma biospectra.

Time frame: Baseline and annually for two years

Correlate plasma biospectra with dopamine transporter neuroimaging data.

Time frame: Baseline and annually for two years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.